This is a paid press release. Contact the press release distributor directly with any inquiries.
Paroxysmal Nocturnal Hemoglobinuria <a href="https://bitcomme.com/weekly-market-wrap/” title=”Weekly market wrap”>Market Forecast Upto 2036: 5 Emerging Therapies Poised to Accelerate Market Growth | DelveInsight
- REGN
- NVO
The expected launch of potential therapies such as Pozelimab +Cemdisiran (Regeneron Pharmaceuticals), Zaltenibart (OMS906; Novo Nordisk), Ruxoprubart (NM8074; NovelMed Therapeutics), NM5072 (NovelMed Therapeutics), ADX-038 (ADARx Pharmaceuticals), KP104 (Kira Pharmaceuticals), and others may increase the paroxysmal nocturnal hemoglobinuria market size in the coming years, assisted by an increase in the diagnosed prevalent population of PNH.
LAS VEGAS, Sept. 17, 2026 /PRNewswire/ — Until 2007, paroxysmal nocturnal hemoglobinuria (PNH) was a life-threatening disorder with limited therapeutic options for controlling hemolysis and thrombosis, the latter being a major contributor to mortality. The treatment landscape underwent a significant transformation with the introduction of the anti-C5 complement inhibitor eculizumab, which substantially reduced hemolysis, lowered transfusion requirements, and, importantly, decreased the risk of thrombosis.
The current disease-modifying treatment approach for PNH is centered on complement inhibition. FDA-approved therapies, including SOLIRIS (eculizumab), ULTOMIRIS (ravulizumab), and EMPAVELI (pegcetacoplan), have established complement inhibition as the standard of care. However, limitations and safety considerations associated with terminal complement inhibition have driven the development of alternative therapeutic approaches. More recent approvals of proximal complement inhibitors, including FABHALTA (iptacopan), VOYDEYA (danicopan), and PIASKY (crovalimab), are expanding treatment options and aim to provide more effective disease control while addressing limitations associated with existing therapies.
Find out the future of the paroxysmal nocturnal hemoglobinuria PNH treatment market @ https://www.delveinsight.com/report-store/paroxysmal-nocturnal-hemoglobinuria-market
The PNH pipeline continues to evolve, with emerging candidates such as Zaltenibart (OMS906), pozelimab, and ruxoprubart (NM8074), among others, highlighting ongoing innovation and the growing diversity of complement-targeted treatment strategies.
Aparna Thakur, Project Manager of Forecasting & Analytics at DelveInsight, said that among the emerging therapies, Pozelimab is expected to generate the highest revenue in the 7MM, followed by Zaltenibart. In a Phase II study, Zaltenibart demonstrated strong efficacy in PNH patients with suboptimal responses to ravulizumab.
Reflecting continued therapeutic innovation and significant unmet medical needs, DelveInsight estimates that the paroxysmal nocturnal hemoglobinuria market across the seven major markets, comprising the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, was valued at approximately USD 1.5 billion in 2025. The market is projected to expand at a CAGR of 7.1% during the forecast period through 2036, driven by the introduction of novel complement-targeted therapies, advances in disease management, increasing awareness and diagnosis of PNH, and ongoing efforts to address breakthrough hemolysis, transfusion dependence, and other limitations associated with existing treatments.
